DexPak 10 Day Taperpak and Sunitinib Malate
Determining the interaction of DexPak 10 Day Taperpak and Sunitinib Malate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Dexamethasone may reduce the blood levels and effects of SUNItinib. Contact your doctor if your symptoms worsen or your condition changes during treatment with these medications. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sunitinib and its pharmacologically active metabolite, both of which are substrates of the isoenzyme. In healthy volunteers, concurrent administration of a single dose of sunitinib with the potent CYP450 3A4 inducer, rifampin, resulted in a 23% and 46% decrease in the combined (i.e., sunitinib plus its primary active metabolite) peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) values, respectively, compared to administration of sunitinib alone.
MANAGEMENT: Alternative agents with no or minimal CYP450 3A4-inducing activity are recommended in patients treated with sunitinib. A dosage increase for sunitinib to a maximum of 87.5 mg daily should be considered if it must be coadministered with CYP450 3A4 inducers such as barbiturates, dexamethasone, efavirenz, nevirapine, rifamycins, and some antiepileptic agents. Patients should be monitored carefully for toxicity, and the sunitinib dosage reduced if necessary.
- "Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.
Generic Name: dexamethasone
Brand name: Baycadron, Dexamethasone Intensol, DexPak 10 Day Taperpak, DexPak 13 DayTaperpak, DexPak 6 DayTaperpak, De-Sone LA, Dexacen-4, Dexasone, Dexasone LA, Solurex, Solurex LA, Decadron, DexPak, TaperDex, Zema-Pak, ZoDex, Zonacort
Synonyms: DexPak 10 Day TaperPak
Generic Name: sunitinib
Brand name: Sutent
Synonyms: Sunitinib, SUNItinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- DexPak 10 Day Taperpak-Sunkist Vitamin C
- DexPak 10 Day Taperpak-Sunmark 12 Hour Allergy Relief
- DexPak 10 Day Taperpak-Sunmark Acid Reducer
- DexPak 10 Day Taperpak-Sunmark Acid Reducer Maximum Strength
- DexPak 10 Day Taperpak-Sunmark Acid Reducer Ranitidine
- DexPak 10 Day Taperpak-Sunmark All Day Allergy-D
- Sunitinib Malate-DexPak 13 DayTaperpak
- Sunitinib Malate-DexPak 6 DayTaperpak
- Sunitinib Malate-DexPak Jr
- Sunitinib Malate-Dexrazoxane
- Sunitinib Malate-Dexrazoxane Hydrochloride
- Sunitinib Malate-Dexrazoxane Intravenous